Trial Profile
Phase II Trial of Ra-223 dichloride in combination with Hormonal Therapy and Denosumab in the Treatment of Patients with Hormone-Positive Bone-Dominant Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Radium 223 chloride (Primary)
- Indications Advanced breast cancer; Bone metastases
- Focus Therapeutic Use
- 16 Dec 2020 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results (n=36) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 24 Jan 2018 Planned End Date changed from 1 Feb 2019 to 1 Feb 2021.